Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$20.04 +1.5%	$18.19	$16.10 ▼ $41.94	$2.48B	0.67	2.37 million shs	1.55 million shs
BEAM Beam Therapeutics	$20.45 +1.9%	$17.97	$13.53 ▼ $35.25	$2.02B	2.07	1.57 million shs	2.00 million shs
BLUE bluebird bio	$4.97	$4.78	$3.20 ▼ $25.10	$48.67M	0.27	447,888 shs	N/A
CRSP CRISPR Therapeutics	$55.09 -0.1%	$44.08	$30.04 ▼ $62.00	$4.76B	1.82	1.96 million shs	2.17 million shs
LLY Eli Lilly and Company	$762.04 -3.5%	$766.32	$677.09 ▼ $972.53	$748.52B	0.4	3.68 million shs	4.10 million shs
PFE Pfizer	$24.59 -0.1%	$24.02	$20.92 ▼ $31.54	$139.92B	0.58	41.96 million shs	47.33 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	+2.07%	+2.81%	+7.92%	+8.52%	-52.00%
BEAM Beam Therapeutics	+2.50%	-6.48%	+20.76%	+18.06%	-26.46%
BLUE bluebird bio	0.00%	0.00%	0.00%	+20.05%	-81.59%
CRSP CRISPR Therapeutics	+4.57%	-8.22%	+32.61%	+45.99%	-12.13%
LLY Eli Lilly and Company	+2.09%	+0.24%	-2.32%	-6.27%	-16.22%
PFE Pfizer	-0.15%	-3.80%	+0.78%	+11.11%	-16.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.3291 of 5 stars	4.3	0.0	0.0	4.4	2.6	2.5	0.6
BEAM Beam Therapeutics	2.081 of 5 stars	3.5	0.0	0.0	0.0	2.5	2.5	0.6
BLUE bluebird bio	1.5998 of 5 stars	3.1	0.0	0.0	0.0	0.0	1.7	1.3
CRSP CRISPR Therapeutics	3.272 of 5 stars	4.3	1.0	0.0	0.0	3.3	2.5	0.6
LLY Eli Lilly and Company	4.9805 of 5 stars	4.4	4.0	3.3	4.0	2.9	1.7	1.9
PFE Pfizer	4.9641 of 5 stars	3.2	3.0	4.2	4.5	2.6	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$39.84	98.81% Upside
BEAM Beam Therapeutics	3.00	Buy	$48.75	138.39% Upside
BLUE bluebird bio	2.25	Hold	$44.60	797.38% Upside
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$71.75	30.24% Upside
LLY Eli Lilly and Company	2.75	Moderate Buy	$1,012.56	32.87% Upside
PFE Pfizer	2.45	Hold	$28.55	16.09% Upside

Current Analyst Ratings Breakdown

Latest BEAM, LLY, CRSP, PFE, APLS, and BLUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
7/11/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$936.00 ➝ $942.00
7/10/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$1,133.00 ➝ $1,135.00
7/8/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
7/2/2025	APLS Apellis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $26.00
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
6/27/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00
6/27/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00
6/26/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/26/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
6/20/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$936.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	3.22	N/A	N/A	$1.84 per share	10.89
BEAM Beam Therapeutics	$63.52M	32.37	N/A	N/A	$8.86 per share	2.31
BLUE bluebird bio	$103.95M	0.47	N/A	N/A	$35.59 per share	0.14
CRSP CRISPR Therapeutics	$37.31M	127.51	N/A	N/A	$22.64 per share	2.43
LLY Eli Lilly and Company	$45.04B	16.03	$13.73 per share	55.49	$15.03 per share	50.70
PFE Pfizer	$63.63B	2.20	$4.36 per share	5.64	$15.62 per share	1.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.79	N/A	N/A	N/A	-28.83%	-99.19%	-25.35%	7/30/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
BLUE bluebird bio	-$211.91M	-$41.32	N/A	N/A	N/A	-565.74%	-322.46%	-53.17%	8/12/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$12.29	62.00	24.49	1.15	22.67%	85.51%	15.74%	8/7/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.82	8.12	0.90	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest BEAM, LLY, CRSP, PFE, APLS, and BLUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q1 2025	BLUE bluebird bio	-$1.91	N/A	N/A	N/A	$45.60 million	N/A
8/7/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.56	N/A	N/A	N/A	$14.40 billion	N/A
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	N/A	N/A	N/A	$13.29 million	N/A
8/5/2025	Q2 2025	PFE Pfizer	$0.57	N/A	N/A	N/A	$13.43 billion	N/A
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.54	N/A	N/A	N/A	$6.44 million	N/A
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A
5/1/2025	Q1 2025	LLY Eli Lilly and Company	$4.64	$3.34	-$1.30	$3.06	$12.77 billion	$12.73 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
BLUE bluebird bio	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.00	0.79%	N/A	48.82%	11 Years
PFE Pfizer	$1.72	6.99%	N/A	124.64%	16 Years

Latest BEAM, LLY, CRSP, PFE, APLS, and BLUE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
5/5/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.73%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.76	4.08	3.62
BEAM Beam Therapeutics	N/A	8.81	8.81
BLUE bluebird bio	0.37	0.51	0.33
CRSP CRISPR Therapeutics	N/A	15.64	15.64
LLY Eli Lilly and Company	2.18	1.37	1.06
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
BEAM Beam Therapeutics	99.68%
BLUE bluebird bio	87.43%
CRSP CRISPR Therapeutics	69.20%
LLY Eli Lilly and Company	82.53%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
BEAM Beam Therapeutics	3.50%
BLUE bluebird bio	1.40%
CRSP CRISPR Therapeutics	4.30%
LLY Eli Lilly and Company	0.13%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	117.51 million	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
BLUE bluebird bio	520	9.79 million	9.59 million	Optionable
CRSP CRISPR Therapeutics	460	86.36 million	82.65 million	Optionable
LLY Eli Lilly and Company	47,000	947.74 million	946.50 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

BEAM, LLY, CRSP, PFE, APLS, and BLUE Headlines

Recent News About These Companies

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off

July 17 at 3:26 PM | benzinga.com

Trade Tracker: Josh Brown Sells Pfizer

July 17 at 2:10 PM | youtube.comY

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

July 17 at 11:47 AM | cnbc.com

3 Ultra-Safe Dividend Stocks That Yield Over 5%

July 17 at 11:47 AM | 247wallst.com

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients

July 17 at 11:18 AM | reuters.com

Pfizer Inc.'s (NYSE:PFE) recent 3.7% pullback adds to one-year year losses, institutional owners may take drastic measures

July 17 at 11:18 AM | finance.yahoo.com

Bristol-Myers Squibb (BMY) and Pfizer (PFE) Stocks Jump on Eliquis Drug Discount

July 17 at 10:43 AM | tipranks.com

Mystic Asset Management Inc. Grows Position in Pfizer Inc. (NYSE:PFE)

July 17 at 9:48 AM | marketbeat.com

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients

July 17 at 9:34 AM | investing.com

Pzena Investment Management LLC Increases Position in Pfizer Inc. (NYSE:PFE)

July 17 at 9:22 AM | marketbeat.com

Commerzbank Aktiengesellschaft FI Trims Stock Position in Pfizer Inc. (NYSE:PFE)

July 17 at 9:14 AM | marketbeat.com

Easterly Investment Partners LLC Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

July 17 at 9:00 AM | marketbeat.com

I Sold Pfizer at a 13% Loss – Here’s Why I’m Choosing Stability Over Risk

July 17 at 8:59 AM | 247wallst.com

Pfizer Inc. (NYSE:PFE) Shares Sold by Pettee Investors Inc.

July 17 at 8:48 AM | marketbeat.com

I Sold Pfizer at a 13% Loss – Here's Why I'm Choosing Stability Over Risk

July 17 at 8:34 AM | 247wallst.com

Concord Wealth Partners Has $1.23 Million Position in Pfizer Inc. (NYSE:PFE)

July 17 at 8:08 AM | marketbeat.com

Verdence Capital Advisors LLC Raises Stake in Pfizer Inc. (NYSE:PFE)

July 17 at 7:38 AM | marketbeat.com

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients

July 17 at 7:21 AM | reuters.com

Pfizer Inc. (NYSE:PFE) Shares Sold by James Investment Research Inc.

July 17 at 7:19 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Sold by Cullen Frost Bankers Inc.

July 17 at 7:12 AM | marketbeat.com

BMS-Pfizer alliance to offer Eliquis at 40% discount to cash-paying patients

July 17 at 7:09 AM | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
BigBear.ai: Why a 90% Rally Could Be Just the Start
By Jeffrey Neal Johnson | July 10, 2025
View BigBear.ai: Why a 90% Rally Could Be Just the Start
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
3 Stocks With Near-Unanimous Buys That Could Rally Higher
By Nathan Reiff | July 2, 2025
View 3 Stocks With Near-Unanimous Buys That Could Rally Higher
3 Notable Stocks Just Split: Which One Could Be the Big Winner?
By Leo Miller | June 26, 2025
View 3 Notable Stocks Just Split: Which One Could Be the Big Winner?

BEAM, LLY, CRSP, PFE, APLS, and BLUE Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$20.04 +0.29 (+1.47%)

Closing price 04:00 PM Eastern

Extended Trading

$20.38 +0.34 (+1.69%)

As of 07:55 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Beam Therapeutics NASDAQ:BEAM

$20.45 +0.38 (+1.89%)

Closing price 04:00 PM Eastern

Extended Trading

$20.50 +0.05 (+0.27%)

As of 07:55 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

bluebird bio NASDAQ:BLUE

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$55.09 -0.05 (-0.09%)

Closing price 04:00 PM Eastern

Extended Trading

$56.58 +1.49 (+2.70%)

As of 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Eli Lilly and Company NYSE:LLY

$762.04 -27.76 (-3.52%)

Closing price 03:59 PM Eastern

Extended Trading

$763.14 +1.10 (+0.14%)

As of 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Pfizer NYSE:PFE

$24.59 -0.02 (-0.07%)

Closing price 03:59 PM Eastern

Extended Trading

$24.58 -0.02 (-0.08%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BEAM, LLY, CRSP, PFE, APLS, and BLUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BEAM, LLY, CRSP, PFE, APLS, and BLUE Earnings

Compare Dividends

Latest BEAM, LLY, CRSP, PFE, APLS, and BLUE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BEAM, LLY, CRSP, PFE, APLS, and BLUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BEAM, LLY, CRSP, PFE, APLS, and BLUE Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

Beam Therapeutics NASDAQ:BEAM

bluebird bio NASDAQ:BLUE

CRISPR Therapeutics NASDAQ:CRSP

Eli Lilly and Company NYSE:LLY

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools